Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 25.
doi: 10.1038/s41596-025-01211-2. Online ahead of print.

Expansion of human hepatocytes and their application in three-dimensional culture and genetic manipulation

Affiliations
Review

Expansion of human hepatocytes and their application in three-dimensional culture and genetic manipulation

Kun Zhang et al. Nat Protoc. .

Abstract

Hepatocytes are one of the most important cell types in the liver, carrying out key functions. They are essential for hepatocyte-based therapy, disease modeling and drug development. However, the availability of primary human hepatocytes (PHHs) is limited by a shortage of donors. It is therefore of great value to expand PHHs in large quantities. Here we provide a detailed protocol for the large-scale expansion of PHHs (proliferating human hepatocytes, ProliHHs) derived from healthy donors and patients with inherited liver diseases, which can be rematured in a three-dimensional culture system. Moreover, we provide a protocol for the genetic manipulation of ProliHHs, including lentivirus transduction and CRISPR-Cas9-mediated knockout and knock-in. The protocol described here will help to realize the full potential of ProliHH-based therapy, organoid-based liver disease modeling and drug screening. The protocol to expand PHHs takes ~1-2 months, the protocol to establish the 3D-cultured ProliHHs takes ~8 d and the protocol to perform gene editing takes ~3 d. Personnel with basic scientific training can conduct these protocols.

PubMed Disclaimer

Conflict of interest statement

Competing interests: L.H., L.Z. and K.Z. declare financial interests via patents filed by Center for Excellence in Molecular Cell Science on the production of ProliHHs.

Similar articles

  • Sexual Harassment and Prevention Training.
    Cedeno R, Bohlen J. Cedeno R, et al. 2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 36508513 Free Books & Documents.
  • The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C, Schatzberg AF. DeBattista C, et al. Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
  • Heterotypic spheroids as a strategy for 3D culture of cryopreserved primary human hepatocytes in stirred-tank systems.
    Arez F, Preiss L, Gal IR, Rebelo SP, Badolo L, Brito C, Spangenberg T, Alves PM. Arez F, et al. SLAS Discov. 2025 Mar;31:100210. doi: 10.1016/j.slasd.2025.100210. Epub 2025 Jan 11. SLAS Discov. 2025. PMID: 39805483
  • Adapting Safety Plans for Autistic Adults with Involvement from the Autism Community.
    Goodwin J, Gordon I, O'Keeffe S, Carling S, Berresford A, Bhattarai N, Heslop P, Nielsen E, O'Connor RC, Ogundimu E, Pelton M, Ramsay SE, Rodgers J, Townsend E, Vale L, Wilson C, Cassidy S. Goodwin J, et al. Autism Adulthood. 2025 May 28;7(3):293-302. doi: 10.1089/aut.2023.0124. eCollection 2025 Jun. Autism Adulthood. 2025. PMID: 40539213
  • Management of urinary stones by experts in stone disease (ESD 2025).
    Papatsoris A, Geavlete B, Radavoi GD, Alameedee M, Almusafer M, Ather MH, Budia A, Cumpanas AA, Kiremi MC, Dellis A, Elhowairis M, Galán-Llopis JA, Geavlete P, Guimerà Garcia J, Isern B, Jinga V, Lopez JM, Mainez JA, Mitsogiannis I, Mora Christian J, Moussa M, Multescu R, Oguz Acar Y, Petkova K, Piñero A, Popov E, Ramos Cebrian M, Rascu S, Siener R, Sountoulides P, Stamatelou K, Syed J, Trinchieri A. Papatsoris A, et al. Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.

References

    1. Sun, Z. et al. Hepatocyte transplantation: the progress and the challenges. Hepatol. Commun. https://doi.org/10.1097/HC9.0000000000000266 (2023).
    1. Hu, W. & Lazar, M. A. Modelling metabolic diseases and drug response using stem cells and organoids. Nat. Rev. Endocrinol. 18, 744–759 (2022). - PubMed - PMC
    1. Grossman, M. et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat. Genet. 6, 335–341 (1994). - PubMed
    1. Hickey, R. D. et al. Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1. Sci. Transl. Med. 8, 349ra399 (2016).
    1. VanLith, C. J. et al. Ex vivo hepatocyte reprograming promotes homology-directed DNA repair to correct metabolic disease in mice after transplantation. Hepatol. Commun. 3, 558–573 (2019). - PubMed - PMC

LinkOut - more resources